These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 22541191)

  • 1. Invited commentary.
    Lee HS; Zo JI
    Ann Thorac Surg; 2012 May; 93(5):1613. PubMed ID: 22541191
    [No Abstract]   [Full Text] [Related]  

  • 2. Invited commentary.
    Antonoff MB
    Ann Thorac Surg; 2013 Sep; 96(3):968. PubMed ID: 23992693
    [No Abstract]   [Full Text] [Related]  

  • 3. Invited commentary.
    Antonoff MB
    Ann Thorac Surg; 2015 May; 99(5):1754. PubMed ID: 25952203
    [No Abstract]   [Full Text] [Related]  

  • 4. Chromosome Instability Drives Tumor Evolution.
    Cancer Discov; 2017 Jun; 7(6):546. PubMed ID: 28487325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biologic Evaluation of Diabetes and Local Recurrence in Non-Small Cell Lung Cancer.
    Yang X; Liu Y; Mani H; Olson J; Clawson G; Caruso C; Bruggeman R; Varlotto JM; Zander DS; Rassaei N
    Pathol Oncol Res; 2017 Jan; 23(1):73-77. PubMed ID: 27411924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic immune markers in non-small cell lung cancer--letter.
    Pandey JP
    Clin Cancer Res; 2011 Dec; 17(24):7835; author reply 7836. PubMed ID: 22147937
    [No Abstract]   [Full Text] [Related]  

  • 7. Can determination of circulating endothelial cells and serum caspase-cleaved CK18 predict for response and survival in patients with advanced non-small-cell lung cancer receiving endostatin and paclitaxel-carboplatin chemotherapy? a retrospective study.
    Chu TQ; Ding H; Garfield DH; Gu AQ; Pei J; Du WD; Han BH
    J Thorac Oncol; 2012 Dec; 7(12):1781-1789. PubMed ID: 23154549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Invited commentary.
    Lim E
    Ann Thorac Surg; 2007 Jan; 83(1):202-3. PubMed ID: 17184662
    [No Abstract]   [Full Text] [Related]  

  • 9. MicroRNA-486 as a Biomarker for Early Diagnosis and Recurrence of Non-Small Cell Lung Cancer.
    Li W; Wang Y; Zhang Q; Tang L; Liu X; Dai Y; Xiao L; Huang S; Chen L; Guo Z; Lu J; Yuan K
    PLoS One; 2015; 10(8):e0134220. PubMed ID: 26237047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. COL11A1 is overexpressed in recurrent non-small cell lung cancer and promotes cell proliferation, migration, invasion and drug resistance.
    Shen L; Yang M; Lin Q; Zhang Z; Zhu B; Miao C
    Oncol Rep; 2016 Aug; 36(2):877-85. PubMed ID: 27373316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional FLT1 Genetic Variation is a Prognostic Factor for Recurrence in Stage I-III Non-Small-Cell Lung Cancer.
    Glubb DM; Paré-Brunet L; Jantus-Lewintre E; Jiang C; Crona D; Etheridge AS; Mirza O; Zhang W; Seiser EL; Rzyman W; Jassem J; Auman T; Hirsch FR; Owzar K; Camps C; Dziadziuszko R; Innocenti F
    J Thorac Oncol; 2015 Jul; 10(7):1067-75. PubMed ID: 26134224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of a reverse transcription-polymerase chain reaction-based five-gene signature in non-small cell lung cancer.
    Ruco L; Scarpino S; Natoli G
    J Thorac Oncol; 2009 May; 4(5):670. PubMed ID: 19395916
    [No Abstract]   [Full Text] [Related]  

  • 13. Prognostic signature of protocadherin 10 methylation in curatively resected pathological stage I non-small-cell lung cancer.
    Harada H; Miyamoto K; Yamashita Y; Taniyama K; Mihara K; Nishimura M; Okada M
    Cancer Med; 2015 Oct; 4(10):1536-46. PubMed ID: 26276761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Role of Cancer Stem Cells in Recurrent and Drug-Resistant Lung Cancer.
    Suresh R; Ali S; Ahmad A; Philip PA; Sarkar FH
    Adv Exp Med Biol; 2016; 890():57-74. PubMed ID: 26703799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Usefulness of Plasma Exosomal MicroRNA-451a as a Noninvasive Biomarker for Early Prediction of Recurrence and Prognosis of Non-Small Cell Lung Cancer.
    Kanaoka R; Iinuma H; Dejima H; Sakai T; Uehara H; Matsutani N; Kawamura M
    Oncology; 2018; 94(5):311-323. PubMed ID: 29533963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic impact of CUG-binding protein 1 expression and vascular invasion after radical surgery for stage IB nonsmall cell lung cancer.
    Zhao J; Zhao Y; Xuan Y; Jiao W; Qiu T; Wang Z; Luo Y
    Indian J Cancer; 2015 Dec; 52 Suppl 2():e125-9. PubMed ID: 26728670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Invited Commentary.
    Shrager J
    Ann Thorac Surg; 2016 Jun; 101(6):2146-7. PubMed ID: 27211933
    [No Abstract]   [Full Text] [Related]  

  • 18. Overexpressed LAPTM4B-35 is a risk factor for cancer recurrence and poor prognosis in non-small-cell lung cancer.
    Kong F; Gao F; Chen J; Sun Y; Zhang Y; Liu H; Li X; Yang P; Zheng R; Liu G; Jia Y
    Oncotarget; 2016 Aug; 7(35):56193-56199. PubMed ID: 27486880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EGFR Mutation Genotype Impact on the Efficacy of Pemetrexed in Patients with Nonsquamous Nonsmall Cell Lung Cancer.
    Igawa S; Sato Y; Ishihara M; Kasajima M; Kusuhara S; Nakahara Y; Otani S; Fukui T; Katagiri M; Sasaki J; Masuda N
    Asian Pac J Cancer Prev; 2016; 17(7):3249-53. PubMed ID: 27509958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic polymorphisms and non-small-cell lung cancer: future paradigms.
    de Mello RA
    Einstein (Sao Paulo); 2014; 12(4):524-6. PubMed ID: 25628210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.